Abstract
Modern medicine has contributed to enhance human longevity and quality of life. On the other hand, an elderly population inhabiting a continuously polluted environment certainly contributes to the raise of cancer development. In this context, anticancer drugs are in high demand in recent decades, and oncology pharmacology is one of the medical fields experiencing a remarkable research activity and development of new drugs. However, anticancer drugs are among the more toxic drugs legally available, and more than 750 different types of adverse reaction scan be attributed to cancer treatments. Adverse drug reactions (ADRs) are among the leading concerns when drug research and development are considered once they are potentially related to therapeutic failures, and consequently, drugs withdraw from the market. ADRs have been estimated to contribute up to 60% of the total costs involved in chemotherapy. The physicochemical drug features are highly related to the onset of ADRs. These drug features are directly involved in key aspects of drug metabolism, like absorption, distribution, efficacy, transformation, excretion, and drug promiscuity. Hepatotoxicity, kidney toxicity, cardiovascular toxicity, neurotoxicity, nausea and vomiting, diarrhea, alopecia, rheumatic manifestations, neutropenia, and thrombocytopenia are among the most common ADRs described in literature, and they are described in the context of the different anticancer drugs families.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adverse Effects
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645–53.
Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924–36.
Zhang X, Zhu Y, Dong S, Zhang A, Lu Y, Li Y, Lv S, Zhang J. Role of oxidative stress in cardiotoxicity of antineoplastic drugs. Life Sci. 2019;232:116526.
Moreau-Bachelard C, Coquan E, LE Tourneau C. N. Imputability of adverse events to anticancer drugs. Engl J Med. 2019;380(19):1873–4.
Cavaletti G, Nicolini G, Marmiroli P. Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci. 2008;3(1):3506–24.
Cridland MD. Antineoplastic and immunosuppressive drugs. Adverse effects and therapeutic problems. Drugs. 1972;3(5):352–65.
Pearce A, Haas M, Viney R. Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review. Appl Health Econ Health Policy. 2013;11(6):619–37.
Wang Z, Yang X, Wang J, Wang S, Mao X, Li M, Zhao Y, Wang W, Qi X, Wu T. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis. J Cancer Res Ther. 2019;15(7):1435–49.
Tchambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Dose adaptation of antineoplastic drugs in patients with liver disease. Drug Saf. 2006;29(6):509–22.
Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33–64.
Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, Blandizzi C. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8(1):61–75.
Chagas CM, Moss S, Alisaraie L. Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski's rule of five. Int J Pharm. 2018;549(1–2):133–49.
Tocchetti CG, Cadeddu C, di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercuro G. From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview. Antioxid Redox Signal. 2019;30(18):2110–53.
Hamnvik OPR. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103(21):1572–87.
Tew KD. Alkylating agents. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 407–19.
Reed E. Cisplatin and its analogs. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 419–26.
Saif MW, Chu E. Antimetabolites. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 427–37.
Rasheed ZA, Rubin EH. Topoisomerase-interacting agents. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 437–47.
Lee JJ, Harris LN. Antimicrotubule agents. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 447–56.
Lorusso PM, Ryan AJ, Boerner SA, HERBST RS. Small-molecule tyrosine kinase inhibitors. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 457–68.
Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction with antibodies. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 469–77.
Gore SD, Baylin SB, Herman JG. Histone deacetylase inhibitors and demethylating agents. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 477–85.
Molineaux CJ, Cews CM. Proteasome inhibitors. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 486–90.
Copur MS, Rose M, Gettinger SN. Miscellaneous chemotherapeutics agents. Chap. 25: Pharmacology of cancer chemotherapy. In: DeVita, Hellman and Rosenberg’s Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 490–5.
Tumor Lysis
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011a;364(19):1844–54.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008a;26(16):2767–78.
Newton HB. Neurologic complications of systemic cancer. Am Fam Physician. 1999;59(4):878–86.
Azoulay E, Moreau D, Alberti C, Leleu G, Adrie C, Barboteu M, et al. Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med. 2000;26(12):1817–23.
Benoit DD, Hoste EA, Depuydt PO, Offner FC, Lameire NH, Vandewoude KH, et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant. 2005;20(3):552–8.
Lanore JJ, Brunet F, Pochard F, Bellivier F, Dhainaut JF, Vaxelaire JF, et al. Hemodialysis for acute renal failure in patients with hematologic malignancies. Crit Care Med. 1991;19(3):346–51.
Tanvetyanon T, Choudhury AM. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004;171(4):1627.
Vaisban E, Braester A, Mosenzon O, et al. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci. 2003;325(1):38–40.
Howard SC, Jones DP, Pui CHN. The tumor lysis syndrome. Engl J Med. 2011b;364(19):1844–54.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008b;26(16):2767–78.
Rahmani B, Patel S, Seyam O, Gandhi J, Reid I, Smith N, Khan SA. Current understanding of tumor lysis syndrome. Hematol Oncol. 2019;37(5):537–47.
Williams SM, Killeen AA. Tumor lysis syndrome. Arch Pathol Lab Med. 2019;143(3):386–93.
Criscuolo M, Fianchi L, Dragonetti G, Pagano L. Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. Expert Rev Hematol. 2016;9(2):197–208.
Russell TB, Kram DE. Tumor lysis syndrome. Pediatr Rev. 2020;41(1):20–6.
Mcbride A, Trifilio S, Baxter N, Gregory TK, Howard SC. Managing tumor lysis syndrome in the era of novel cancer therapies. J Adv Pract Oncol. 2017;8(7):705–20.
Greguska C. Managing tumor lysis syndrome. JAAPA. 2021;34(1):10–3.
Klemencic S, Perkins J. Diagnosis and Management of Oncologic Emergencies. West J Emerg Med. 2019;20(2):316–22.
Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–13; quiz S14–9.
Giammarco S, Chiusolo P, Piccirillo N, Di Giovanni A, Metafuni E, Laurenti L, Sica S, Pagano L. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10(2):147–54.
Findakly D, Luther RD III, Wang J. Tumor lysis syndrome in solid tumors: A comprehensive literature review, new insights, and novel strategies to improve outcomes. Cureus. 2020;12(5):e8355.
Durani U, Hogan WJ. Emergencies in haematology: tumour lysis syndrome. Br J Haematol. 2020;188(4):494–500.
Tumor Extravasation
Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer Cell. 2017;32(3):282–93.
Boulanger J, Ducharme A, Dufour A, Fortier S, Almanric K. Management of the extravasation of anti-neoplastic agents. Comité de l’évolution de la pratique des soins pharmaceutiques (CEPSP); Comité de l’évolution des pratiques en oncologie (CEPO). Support Care Cancer. 2015;23(5):1459–71.
Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.; ESMO Guidelines Working Group. Ann Oncol. 2012;23(Suppl 7):vii167–73.
Jackson-Rose J, Del Monte J, Groman A, Dial LS, Atwell L, Graham J, O’neil SEMLERR, O’sullivan M, Truini-Pittman L, Cunningham TA, Roman-Fischetti L, Costantinou E, Rimkus C, Banavage AJ, Dietz B, Colussi CJ, Catania K, Wasko M, Schreffler KA, West C, Siefert ML, Rice RD. Chemotherapy extravasation: establishing a National Benchmark for incidence among cancer centers. Clin J Oncol Nurs. 2017;21(4):438–45.
Harrold K. Managing cytotoxic chemotherapy extravasation: use of saline washout. Br J Nurs. 2015;24(8):S36–7.
Yadavalli S, Jayaram S, Manda SS, Madugundu AK, Nayakanti DS, Tan TZ, Bhat R, Rangarajan A, Chatterjee A, Gowda H, Thiery JP, Kumar P. Data-driven discovery of extravasation pathway in circulating tumor cells. Sci Rep. 2017;7:43710.
Bahrami M, Karimi T, Yadegarfar G, Norouzi A. Assessing the quality of existing clinical practice guidelines for chemotherapy drug extravasation by appraisal of guidelines for research and evaluation II. Iran J Nurs Midwifery Res. 2019;24(6):410–6.
Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen ZR, Mardor Y. Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS One. 2012;7(12):e52008.
De Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. Onkologie. 2013;36(3):127–35.
Harrold K, Gould D, Drey N. The management of cytotoxic chemotherapy extravasation: a systematic review of the literature to evaluate the evidence underpinning contemporary practice. Eur J Cancer Care (Engl). 2015;24(6):771–800.
Others
Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of uncommon chemotherapy-induced emergencies. Lancet Oncol. 2011;12(8):806–14.
Wagner J, Arora S. Oncologic metabolic emergencies. Hematol Oncol Clin North Am. 2017;31(6):941–57.
Mccurdy MT, Shanholtz CB. Oncologic emergencies. Crit Care Med. 2012;40(7):2212–22.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Frigo, L., da Fonseca, G.A.M.D., Favero, G.M., Maria, D.A. (2022). Managing Issues: Tumor Lysis, Extravasation, Adverse Effects, and Others. In: Schmidt, C.W.P., Otoni, K.M. (eds) The Golden Guide to Oncologic Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-98596-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-98596-7_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-98595-0
Online ISBN: 978-3-030-98596-7
eBook Packages: MedicineMedicine (R0)